Clinical Trials
2 trialsNCT02494596 2015-11-10
A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT01463982 2015-04-23
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
Hanmi Pharmaceutical Company Limited
Phase 1 Completed